Single and Multiple Dose Study of MK-2828 in Healthy Japanese Participants

A Single and Multiple Dose Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-2828 in Healthy Japanese Participants

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031250736

Enrollment

Registered

2026-02-17

Start date

2026-03-25

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure with preserved ejection fraction

Interventions

Panel A: MK-2828 10mg or 60 mg single oral dose administration. Panel B: MK-2828 40 mg single oral dose administeration. Panel C: MK-2828 20 mg QD for 12 days multiple oral dose administration.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy male and female participants between the ages of 24 and 55 years

Exclusion criteria

Exclusion criteria: Has a history of clinically significant abnormalities or diseases

Design outcomes

Primary

Measure	Time frame
Adverse events, discontinuation of study intervention due to adverse event(s)	—

Secondary

Measure	Time frame
Pharmacokineticks	—

Contacts

Public ContactMSDJRCT inquiry mailbox

MSD K.K.

msdjrct@msd.com+81-3-6272-1957

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Sep 19, 2026